GlassScriptPhysician profile
Kathrine E Lupo
NPI 1528279932
$2,059.04
in general payments reported to CMS, 2019-2025
24 companies · $660 in 2025
The $660 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $96.62 · 2022: $86.58 · 2023: $341 · 2024: $228 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.39 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $553.58 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $430.18 | 2023-2025 | Veozah |
| Abbvie INC. | $209.36 | 2019-2023 | |
| Sage Therapeutics, LLC | $98.92 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $97.39 | 2019-2024 | Paragard T 380a |
| Hologic Sales and Service, LLC | $93.01 | 2024-2025 | Aptima, Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $91.10 | 2019-2020 | |
| Therapeuticsmd, INC. | $62.58 | 2019 | |
| Sumitomo Pharma America, INC. | $62.52 | 2024-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $50.59 | 2020-2023 | |
| Amag Pharmaceuticals, INC. | $42.60 | 2019 | |
| Mylan Pharmaceuticals INC. | $39.11 | 2019 | |
| Shield Therapeutics INC | $37.11 | 2025 | |
| Medtronic, INC. | $23.60 | 2022 | |
| Organon LLC | $22.61 | 2025 | Nexplanon |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $21.44 | 2025 | Phexxi, Solosec, Phexx |
| Roche Diagnostics Corporation | $21.21 | 2019 | |
| Amgen INC. | $20.72 | 2019 | |
| Aspira Women'S Health INC | $18.03 | 2020 | |
| Exeltis, USA INC. | $14.34 | 2020 | |
| Dysis Medical, INC. | $13.62 | 2019 | |
| Millicent US INC | $13.56 | 2025 | Intrarosa, Femring |
| Smith+Nephew, INC. | $11.91 | 2019 | |
| Meditrina | $9.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathrine Lupo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.